Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.74 USD | -0.72% | +1.54% | -12.84% |
05-10 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
05-10 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.84% | 91.34B | |
+29.37% | 682B | |
+30.35% | 586B | |
-3.52% | 364B | |
+17.87% | 327B | |
+3.86% | 285B | |
+15.81% | 240B | |
+10.38% | 209B | |
-8.38% | 203B | |
+7.42% | 165B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Sector Update: Health Care Stocks Steady Tuesday Afternoon